WANNAMAKER, MARION W.,BEMIS, GUY W.,CHARIFSON, PAUL S.,LAUFFER, DAVID J.,MULLICAN, MICHAEL D.,MURCKO, MARK A.,WILSON, KEITH P.,JANETKA, JAMES W.,DAVIES, ROBERT J.,GRILLOT, ANNE-LAURE,SHI, ZHAN,FORSTER
申请号：
CA2324226
公开号：
CA2324226C
申请日:
1999.03.19
申请国别(地区):
CA
年份:
2012
代理人:
摘要：
The present invention relates to novel classes of compounds which are caspaseinhibitors, in particular interleukin-1.beta. converting enzyme ("ICE")inhibitors. This invention also relates to pharmaceutical compositionscomprising these compounds. The compounds and pharmaceutical compositions ofthis invention are particularly well suited for inhibiting caspase activityand consequently, may be advantageously used as agents against interleukin-1-("IL-1"), apoptosis-, interferon-.gamma. inducing factor- (IGIF), orinterferon-.gamma.- ("IFN-.gamma.") mediated diseases, including inflammatorydiseases, autoimmune diseases, destructive bone disorders, proliferativedisorders, infectious diseases, and degenerative diseases. This invention alsorelates to methods for inhibiting caspase activity and decreasing IGIFproduction and IFN-.gamma. production and methods for treating interleukin-1,apoptosis-, and interferon-.gamma.- mediated diseases using the compounds andcompositions of this invention. This invention also relates to methods ofpreparing the compounds of this invention.
